Graph‐based optimization of epitope coverage for vaccine antigen design

Epigraph is a recently developed algorithm that enables the computationally efficient design of single or multi‐antigen vaccines to maximize the potential epitope coverage for a diverse pathogen population. Potential epitopes are defined as short contiguous stretches of proteins, comparable in length to T‐cell epitopes. This optimal coverage problem can be formulated in terms of a directed graph, with candidate antigens represented as paths that traverse this graph. Epigraph protein sequences can also be used as the basis for designing peptides for experimental evaluation of immune responses in natural infections to highly variable proteins. The epigraph tool suite also enables rapid characterization of populations of diverse sequences from an immunological perspective. Fundamental distance measures are based on immunologically relevant shared potential epitope frequencies, rather than simple Hamming or phylogenetic distances. Here, we provide a mathematical description of the epigraph algorithm, include a comparison of different heuristics that can be used when graphs are not acyclic, and we describe an additional tool we have added to the web‐based epigraph tool suite that provides frequency summaries of all distinct potential epitopes in a population. We also show examples of the graphical output and summary tables that can be generated using the epigraph tool suite and explain their content and applications. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Statistics in Medicine published by John Wiley & Sons Ltd.

[1]  B. Korber,et al.  Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E , 2016, Science.

[2]  Matthew S. Lewis,et al.  Immune clearance of highly pathogenic SIV infection , 2013, Nature.

[3]  James Theiler,et al.  Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine , 2016, Scientific Reports.

[4]  James Theiler,et al.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.

[5]  P. Kaleebu,et al.  Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. , 2008, Vaccine.

[6]  Jerome H. Kim,et al.  Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys , 2013, Cell.

[7]  M S Waterman,et al.  Identification of common molecular subsequences. , 1981, Journal of molecular biology.

[8]  B. Korber,et al.  Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost , 2015, Journal of Virology.

[9]  E. Rosenberg,et al.  Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides , 2004, Journal of Virology.

[10]  Barry O'Sullivan,et al.  A fixed-parameter algorithm for the directed feedback vertex set problem , 2008, JACM.

[11]  Bette Korber,et al.  Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys , 2010, Nature Medicine.

[12]  Norman L. Letvin,et al.  T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces , 2009, Journal of Virology.

[13]  Karina Yusim,et al.  Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage , 2012, PloS one.

[14]  J. Mellors,et al.  Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. , 2016, The Journal of infectious diseases.

[15]  Alan S. Perelson,et al.  Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing , 2010, PloS one.

[16]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[17]  Matthew S. Lewis,et al.  Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms , 2013, Science.

[18]  O. Yang,et al.  Short Conserved Sequences of HIV-1 Are Highly Immunogenic and Shift Immunodominance , 2014, Journal of Virology.

[19]  P. Pevzner,et al.  An Eulerian path approach to DNA fragment assembly , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Elliott,et al.  Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Tavis K. Anderson,et al.  Broad Protection against Avian Influenza Virus by Using a Modified Vaccinia Ankara Virus Expressing a Mosaic Hemagglutinin Gene , 2014, Journal of Virology.

[22]  A. McMichael,et al.  Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  N. Russell,et al.  Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. , 2008, Vaccine.

[24]  J. Mullins,et al.  Altered Response Hierarchy and Increased T-Cell Breadth upon HIV-1 Conserved Element DNA Vaccination in Macaques , 2014, PloS one.

[25]  Feng Gao,et al.  Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. , 2012, The Journal of clinical investigation.

[26]  B. Walker,et al.  Mosaic HIV-1 Gag Antigens Can Be Processed and Presented to Human HIV-Specific CD8+ T Cells , 2011, The Journal of Immunology.

[27]  Robert E. Tarjan,et al.  Depth-First Search and Linear Graph Algorithms , 1972, SIAM J. Comput..

[28]  Bette Korber,et al.  Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys , 2012, Journal of Virology.

[29]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[30]  de Ng Dick Bruijn.  A combinatorial problem , 1946 .

[31]  E. Rybicki,et al.  Justification for the inclusion of Gag in HIV vaccine candidates , 2016, Expert review of vaccines.

[32]  B. Korber,et al.  Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. , 2012, Virology.

[33]  B. Korber,et al.  Hepatitis C Genotype 1 Mosaic Vaccines Are Immunogenic in Mice and Induce Stronger T-Cell Responses than Natural Strains , 2012, Clinical and Vaccine Immunology.

[34]  Pavel A Pevzner,et al.  How to apply de Bruijn graphs to genome assembly. , 2011, Nature biotechnology.

[35]  Feng Gao,et al.  Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.

[36]  Alexandra Nunes,et al.  A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance , 2016, Front. Immunol..

[37]  D. Strick,et al.  Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load , 2003, Journal of Virology.

[38]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[39]  Peter B Gilbert,et al.  Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. , 2006, Vaccine.

[40]  Andrew L. Ferguson,et al.  Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. , 2013, Immunity.

[41]  Bette Korber,et al.  Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine , 2007, PloS one.

[42]  Alan S. Perelson,et al.  Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape , 2012, PLoS pathogens.

[43]  David S. Johnson,et al.  Computers and Intractability: A Guide to the Theory of NP-Completeness , 1978 .

[44]  Robert Giegerich,et al.  A systematic approach to dynamic programming in bioinformatics , 2000, Bioinform..